Spyre Therapeutics
SYRE
93.47
-4.16
-4.26%
Spyre Therapeutics
US · SYRE
#1646 by market cap
Listed 1970
93.47
-4.16
-4.26%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
About Spyre Therapeutics
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.
- Founded
- 2013
- CEO
- Dr. Cameron Turtle, D.Phil.
- Employees
- 102
- Headquarters
- Waltham, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- spyre.com
Company profile
- Exchange
- US
- Symbol
- SYRE
- Market-cap rank
- #1646
- Listing date
- 1970-01-01
- Market cap
- 8.88B
- Float cap
- 8.65B
- Shares out
- 94.97M
- Float shares
- 92.51M
Sectors & themes
Biotechnology
Fractional Shares JP
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Spyre Therapeutics discussion 0 comments